2Bonner JA,Harari PM,Giralt J,et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J].N Engl J Med,2006,354(6):567-578.
3Vermorken JB,Trigo J,Hitt R,et al.Open-label,uncontrolled,multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum based therapy[J].J Clin Oncol,2007,25(16):2171-2177.
4Saltz LB,Meropol NJ,Loehrer PJ Sr,et al.Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J].J Clin Oncol,2004,22(7):1201-1208.
5Baselga J,Pfister D,Cooper MR,et al.Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin[J].J Clin Oncol,2000,18(4):904-914.
二级参考文献16
1Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy [ J ]. Drugs, 2000,60(Suppl 1) :S15 - S23.
2Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab [ J ] . Eur J Cancer, 2001,37 ( Suppl 4) : S16 - S22.
4Ciardiello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy [ J ]. Expert Opin Investig Drugs, 2002, 11 (6) : 755 -768.
5Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11)against human colorectal tumor xenografts [ J ]. Clin Cancer Res, 2002,8 ( 5 ) : 994 -1003.
6Bianco C, Bianco R,Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide [ J ]. Clin Cancer Res,2000,6( 11 ) :4343 - 4350.
7Folprecht G, Lutz MP, Schoeffski P, et al. Pharmacokinetic ( PK )evaluation of cetuximab in combination with weekly irinotecan( CPT-11 )and 24h infusional 5-FU/folinic acid(FA)as first line treatment in patients(pts) with epidermal growth factor receptor ( EGFR)-positive metastatic colorectal cancer(MCRC) [J]. Proc Am Soc Clin Oncol ,2003,22 (2) : 222.
8Baselga J, Pfister D, Cooper MR, et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and incombination with cisplatin [ J ]. J Clin Oncol , 2000,18 ( 4 ) : 904 -914.
9Raoul JL, Van Laethem JL, Mitry E, et al. Phase Ⅱ study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid(FA) in patients(pts) with metastatic,epidermal growth factor receptor(EGFR)-expressing colorectal cancer(CRC)[J]. Eur J Cancer, 2003,1 ( Suppl 5) : S89.
10Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225)plus weekly irinotecan (CPT-11), fluorouracil and leucovorin in colorectal cancer that expresses the epidermal growth factor receptor[abstract no.536][A].38^th Annual Meeting of the American Society of clinical Oncology[ C ], Orlando, 2002.
